ncRNA basic information ncRNA ID: MIMAT0004692 ncRNA Database: miRBase ncRNA Name: miR-340-5p ncRNA Type: miRNA ncRNA Expression: up-regulated ncRNA Method: qRT-PCR ncRNA Target Gene: LGR5 ncRNA Pathway: Wnt/Beta-catenin pathway Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB01248 (APRD00932) Drug Name: Docetaxel Drug Method: In our present study, we firstly detected miR-340-5p expression in breast cancer cell lines and found lower expression of miR-340-5p in breast cancer cell lines (MCF-7, MDA-MB-231, BT-549, ZR-75-1) through qRT-PCR. Overexpressed miR-340-5p inhibited cell proliferation and drug resistance to docetaxel with enhanced cell apoptosis of breast cancer cells. Through bioinformatic prediction, we found that LGR5 was a potential target of miR-340-5p. LGR5 was highly expressed in breast cancer cells. Relative expression of LGR5 was negatively regulated by miR-340-5p. Knockdown of LGR5 also inhibited cell proliferation and drug resistance to docetaxel with enhanced cell apoptosis of breast cancer cells. Moreover, knockdown of LGR5 decreased the expression of Beta-catenin, c-myc, Survivin. The activation of Wnt/Beta-catenin pathway contracted the effects of LGR5 siRNA, indicating that LGR5 siRNA inhibited cell proliferation and drug resistance with induced apoptosis via suppressing Wnt/Beta-catenin signaling pathway in breast cancer. Drug Response: sensitive

Cancer basic information Cancer: breast cancer Tissue/Cell: cell lines (MCF-7, MDA-MB-231, BT-549, ZR-75-1)

Other information Title: LGR5 acts as a target of miR-340-5p in the suppression of cell progression and drug resistance in breast cancer via Wnt/Beta-catenin pathway. Journal: Gene Published: 2019 PubMed ID: 30300682